Reappraisal of the Subtropical Guidelines on Palivizumab Prophylaxis in Congenital Heart Disease.
Ontology highlight
ABSTRACT: Objective: To define the impact of associated abnormalities on the efficacy of the novel subtropical guidelines for palivizumab prophylaxis on respiratory syncytial virus (RSV)-related hospitalizations in patients with hemodynamically significant congenital heart disease (hsCHD). Method: This prospective study enrolled every patient seen at a tertiary care center for hsCHD, who was born between 2014 and 2018 and received at least 1 dose of palivizumab, according to the subtropical guidelines. The patients were followed until the age of 2 years. Results: A total of 772 patients (49% male) were enrolled. Cyanotic CHD was seen in 46% of patients, of whom 23% had associated abnormalities. Lung/airway abnormalities (14%) were the most common followed by the genetic syndrome
SUBMITTER: Chiu SN
PROVIDER: S-EPMC8767946 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA